ATE548025T1 - Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung - Google Patents

Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung

Info

Publication number
ATE548025T1
ATE548025T1 AT04740073T AT04740073T ATE548025T1 AT E548025 T1 ATE548025 T1 AT E548025T1 AT 04740073 T AT04740073 T AT 04740073T AT 04740073 T AT04740073 T AT 04740073T AT E548025 T1 ATE548025 T1 AT E548025T1
Authority
AT
Austria
Prior art keywords
treatment
pulmonary
present
hypertensia
methods
Prior art date
Application number
AT04740073T
Other languages
English (en)
Inventor
Imtiaz Chaudry
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE548025T1 publication Critical patent/ATE548025T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04740073T 2003-06-27 2004-06-18 Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung ATE548025T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/609,233 US20040265238A1 (en) 2003-06-27 2003-06-27 Inhalable formulations for treating pulmonary hypertension and methods of using same
PCT/EP2004/006629 WO2005000270A2 (en) 2003-06-27 2004-06-18 Inhalable formulations for treating pulmonary hypertension and methods of using same

Publications (1)

Publication Number Publication Date
ATE548025T1 true ATE548025T1 (de) 2012-03-15

Family

ID=33540807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04740073T ATE548025T1 (de) 2003-06-27 2004-06-18 Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung

Country Status (16)

Country Link
US (3) US20040265238A1 (de)
EP (1) EP1638525B1 (de)
JP (3) JP5571867B2 (de)
KR (3) KR20060026070A (de)
CN (1) CN1822817B (de)
AT (1) ATE548025T1 (de)
AU (2) AU2004251014B8 (de)
BR (1) BRPI0411904B8 (de)
CA (1) CA2530632C (de)
ES (1) ES2384384T3 (de)
HK (1) HK1093017A1 (de)
MX (1) MXPA05013539A (de)
PL (1) PL1638525T3 (de)
RU (2) RU2491072C2 (de)
WO (1) WO2005000270A2 (de)
ZA (1) ZA200600773B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3874419B2 (ja) * 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
US20060217421A1 (en) 2003-05-09 2006-09-28 Hajimu Kurumatani Fortifier
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
WO2005058303A1 (en) * 2003-12-16 2005-06-30 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
EP1753429A1 (de) * 2004-05-28 2007-02-21 Vertex Pharmaceuticals Incorporated Modulatoren von muscarinischen rezeptoren
AU2005282065B2 (en) * 2004-09-10 2013-02-07 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
EP1898951B1 (de) * 2005-06-27 2013-02-27 Daiichi Sankyo Company, Limited Pharmazeutisches präparat mit einem angiotensin-ii-rezeptor-antagonisten und einem calciumkanalblocker
JP2009511594A (ja) * 2005-10-14 2009-03-19 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド ニモジピンの液体製薬学的組成物
CN101495122B (zh) 2006-05-15 2011-10-05 联合治疗公司 使用定量吸入器给予曲前列尼
CA2653744C (en) * 2006-05-26 2018-01-16 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
WO2008002929A2 (en) * 2006-06-26 2008-01-03 Inverseon, Inc. Heterologous cross-sensitization for improved agonist activity
WO2008019106A1 (en) * 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
WO2008149201A2 (en) * 2007-06-06 2008-12-11 Emcure Pharmaceuticals Limited Stable pharmaceutical composition
BRPI0812686A2 (pt) * 2007-07-24 2011-10-18 Viridis Biopharma Pvt Ltd meios de aplicação de análogos da vitamina k e derivados para o tratamento de condições de doença humana e distúrbios
WO2009086470A2 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
WO2010036798A1 (en) * 2008-09-25 2010-04-01 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
KR101544246B1 (ko) * 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
CN101891596B (zh) * 2009-05-22 2013-12-11 上海天伟生物制药有限公司 一种化合物及其制备方法和用途
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
US20120184622A1 (en) * 2009-08-07 2012-07-19 Scipharm Sarl Composition for the treatment of cystic fibrosis
PT2627173E (pt) 2010-10-12 2015-07-24 Medicines Co Formulações de clevidipina em emulsão contendo agentes antimicrobianos
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CN102580090A (zh) * 2011-01-06 2012-07-18 北京水圣木科技有限责任公司 一种用于治疗高血压的颗粒剂
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
RU2559424C1 (ru) * 2014-06-18 2015-08-10 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России) Способ подбора лекарственной терапии больным с идиопатической легочной гипертензией
RU2593016C2 (ru) * 2014-12-15 2016-07-27 Федеральное государственное бюджетное учреждение науки Институт теоретической и прикладной механики им. С.А. Христиановича Сибирского отделения Российской академии наук (ИТПМ СО РАН) Способ лечения артериальной гипертензии путем ингаляционного введения аэрозоля гипотензивного препарата
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
JP6930693B2 (ja) * 2015-12-01 2021-09-01 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． ジルチアゼムの非経口投薬形態
IL260823B2 (en) * 2016-01-29 2024-08-01 Mannkind Corp Dry powder inhaler
HU231031B1 (hu) * 2016-03-23 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Megnövelt stabilitású epoprostenol nátrium és eljárás előállítására
US20210369664A1 (en) * 2016-07-20 2021-12-02 Tohoku University Prophylactic or therapeutic agent for pulmonary hypertension which comprises ppar? agonist
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
US20210386944A1 (en) * 2018-10-12 2021-12-16 Sanotize Research Development Corp. Gas-evolving compositions and container and delivery systems
EP3750528A1 (de) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Zusammensetzungen zur behandlung von dystrophien und myotonie
EP4135707A1 (de) 2020-04-17 2023-02-22 United Therapeutics Corporation Treprostinil zur verwendung bei der behandlung von intersitiellen lungenerkrankungen
WO2023178283A1 (en) 2022-03-18 2023-09-21 Epicentrx, Inc. Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
WO2023206444A1 (zh) * 2022-04-29 2023-11-02 兆科药业（广州）有限公司 一种曲前列尼尔软雾吸入剂
CN114652704A (zh) * 2022-04-29 2022-06-24 兆科药业（广州）有限公司 一种曲前列尼尔软雾吸入剂
WO2023215227A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Systems and methods to improve exercise tolerance
WO2023215229A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Compositions and methods for treatment of pulmonary hypertension
TW202408485A (zh) 2022-06-13 2024-03-01 美商埃皮辛特瑞科斯公司 用於減少癌症治療中不良副作用之組合物及方法
CN115624522B (zh) * 2022-09-07 2024-06-11 上海交通大学医学院附属第九人民医院 一种能够预防肺动脉压急性增高的载药乙醇注射液及其制备方法与应用
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
WO2024124152A1 (en) 2022-12-08 2024-06-13 Epicentrx, Inc. Rrx-001 for the treatment of a hemoglobinopathy

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2414918A (en) * 1941-09-23 1947-01-28 Abramson Harold Alexander Solutions for the improved nebulization therapy of the lungs and bronchioles
GB1114313A (en) * 1964-11-19 1968-05-22 Wyeth John & Brother Ltd Pharmaceutical compositions
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
USD275732S (en) * 1982-05-21 1984-10-02 Dey Laboratories, Inc. Liquid dispensing container
CH657779A5 (de) * 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
FR2568773B1 (fr) * 1984-08-10 1989-03-03 Sandoz Lab Nouvelles compositions pharmaceutiques administrables par voie nasale
USD289609S (en) * 1984-11-29 1987-05-05 Dey Laboratories, Inc. Liquid dispensing container
USD296869S (en) * 1985-09-18 1988-07-26 Dey Laboratories, Inc. Liquid dispensing container
DE3887591T2 (de) * 1987-07-07 1994-05-19 Beecham Group Plc Pinacidil zur Behandlung von pulmonaler Hypertonie oder Rechtsversagen.
USD317715S (en) * 1989-10-10 1991-06-25 Dey Laboratories, Inc. Liquid dispensing container
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
SE9000207L (sv) * 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
ES2097208T3 (es) 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.
SG47527A1 (en) * 1990-12-05 1998-04-17 Gen Hospital Corp Devices for treating pulmonary vasoconstriction and asthma
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
GB9118830D0 (en) * 1991-09-03 1991-10-16 Minnesota Mining & Mfg Medical aerosol formulations
DE4215317C2 (de) 1992-05-09 1994-04-21 Ver Glaswerke Gmbh Vorrichtung zum Beschichten einer Oberfläche einer Glasscheibe
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
US20020132787A1 (en) * 1993-04-07 2002-09-19 Mohammed Eljamal Compositions and methods for nucleic acid delivery to the lung
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
JPH0753358A (ja) * 1993-08-17 1995-02-28 Teijin Ltd 吸入剤
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
DE4435422A1 (de) * 1994-10-04 1996-04-18 Basf Ag Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion
GB9601202D0 (en) 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
ATE219942T1 (de) * 1997-03-20 2002-07-15 Novo Nordisk As Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
PT1002792E (pt) * 1997-04-04 2004-12-31 Mitsubishi Pharma Corp Compostos de 2-aminopropano-1,3-diol, sua utilizacao medicinal e intermediariosda sintese dos mesmos
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
RU2161483C2 (ru) 1998-02-04 2001-01-10 Мурина Марина Алексеевна Средство для угнетения активности тромбоцитов
US20020086852A1 (en) 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
AU4841799A (en) * 1998-06-29 2000-01-17 Nastech Pharmaceutical Company, Inc Methods and pharmaceutical formulations for preventing and treating motion sickness
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US6121300A (en) 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
AU766703B2 (en) 1998-11-12 2003-10-23 Frank G Pilkiewicz An inhalation system
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
EP1143930B8 (de) * 1999-09-11 2008-03-19 Glaxo Group Limited Fluticasonpropionat arzneizubereitung
US6174906B1 (en) * 1999-10-01 2001-01-16 Smithkline Beecham Corporation Endothelin receptor antagonists
CO5270018A1 (es) * 1999-12-11 2003-04-30 Glaxo Group Ltd Distribuidor de medicamento
US20010031738A1 (en) * 2000-01-19 2001-10-18 Schwarz Margaret A. Methods and pharmaceutical formulations for the treatment of pulmonary hypertension and methods for screening compounds useful in the treatment of pulmonary hypertension
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
MXPA02006352A (es) 2000-01-26 2002-11-29 Warner Lambert Co Combinaciones del inhibidor ace con el antagonista vasopresina.
DE60128540T2 (de) * 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
JP3691341B2 (ja) * 2000-05-16 2005-09-07 日新製鋼株式会社 精密打抜き性に優れたオーステナイト系ステンレス鋼板
GB0014883D0 (en) 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US20020142970A1 (en) 2000-10-10 2002-10-03 Vaughan Douglas E. Method for treating or preventing cardiovascular disease via administration of an ace inhibitor
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
CN1287856C (zh) 2000-10-31 2006-12-06 德比奥药物股份有限公司 Epi－hne蛋白质干粉
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
DE10113366A1 (de) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
US20020090388A1 (en) * 2000-12-01 2002-07-11 Humes H. David Intravascular drug delivery device and use therefor
US20040048905A1 (en) * 2000-12-18 2004-03-11 Daley William Lionel Therapeutic combination of amlodipine and benazepril
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2002094237A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of beta-blockers through an inhalation route
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
AU2002355419A1 (en) * 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
WO2003015747A1 (en) * 2001-08-13 2003-02-27 Genomed, Llc Method to treat pulmonary hypoplasia in the newborn
AU2002336401A1 (en) 2001-09-05 2003-03-18 Cyterra Corporation Nitric oxide generation
FR2831446B1 (fr) * 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
US20060258652A1 (en) * 2002-11-22 2006-11-16 Haj-Yehia Abdullah I Beta-blockers having antioxidant and no-donor activity
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070117861A1 (en) * 2003-11-12 2007-05-24 University Of South Carolina Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic-amp specific phosphodiesterase inhibitors
US20050191245A1 (en) * 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
US20110207555A1 (en) * 2010-02-24 2011-08-25 Bridgestone Sports Co., Ltd. Multiple-piece golf ball

Also Published As

Publication number Publication date
BRPI0411904B8 (pt) 2021-05-25
WO2005000270A3 (en) 2005-05-12
EP1638525B1 (de) 2012-03-07
JP5571867B2 (ja) 2014-08-13
US9498437B2 (en) 2016-11-22
US20040265238A1 (en) 2004-12-30
RU2006102206A (ru) 2006-08-27
EP1638525A2 (de) 2006-03-29
KR20060026070A (ko) 2006-03-22
JP2012001549A (ja) 2012-01-05
CN1822817B (zh) 2012-10-10
CA2530632C (en) 2012-03-06
HK1093017A1 (en) 2007-02-23
PL1638525T3 (pl) 2012-10-31
US20110265786A1 (en) 2011-11-03
US20060104913A1 (en) 2006-05-18
ZA200600773B (en) 2007-05-30
JP5981109B2 (ja) 2016-08-31
AU2004251014B2 (en) 2010-11-25
BRPI0411904A (pt) 2006-08-08
RU2010152753A (ru) 2012-06-27
KR20120068052A (ko) 2012-06-26
JP2014240443A (ja) 2014-12-25
CA2530632A1 (en) 2005-01-06
KR20140141728A (ko) 2014-12-10
AU2004251014A1 (en) 2005-01-06
AU2011200464B2 (en) 2012-08-09
BRPI0411904B1 (pt) 2020-11-03
MXPA05013539A (es) 2006-03-09
KR101824298B1 (ko) 2018-01-31
RU2491072C2 (ru) 2013-08-27
CN1822817A (zh) 2006-08-23
AU2011200464A1 (en) 2011-02-24
ES2384384T3 (es) 2012-07-04
JP2007519604A (ja) 2007-07-19
JP6141811B2 (ja) 2017-06-07
AU2004251014B8 (en) 2011-02-10
WO2005000270A2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
ATE548025T1 (de) Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DK1682074T3 (da) Præparater og fremgangsmåder til sund graviditet
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
WO2006052899A3 (en) Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
NO20080697L (no) Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
HK1110207A1 (en) Ophthalmic compositions and methods of using the same
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
ATE457177T1 (de) Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
WO2007015175A3 (en) Use of pp-1 inhibitors to prevent missplicing events
EP1801232A4 (de) Verfahren zum screening eines transmembranenzymhemmstoffs
EP1248641A4 (de) Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах